PGHH Announces Key Management Changes: New CFO Appointed, Directors Re-designated
PGHH announced changes in its leadership. Mr. Ghanashyam Hegde will be re-designated as Non-Executive Director from July 1, 2026, after ceasing as Company Secretary on June 30, 2026. Ms. Srividya Srinivasan is appointed as Executive Director and CFO from July 1, 2026, for a five-year term.
Changes in key managerial personnel, including the CFO and Company Secretary, can have a medium-term impact on the company's operations and strategic direction.
The announcement details routine changes in directorship and key managerial personnel, with no immediate financial impact or significant positive/negative news.
Procter & Gamble Hygiene and Health Care Limited (PGHH) announced significant changes in its leadership team, approved by the Board of Directors at a meeting held on May 28, 2026.
Mr. Ghanashyam Hegde will cease to be Company Secretary and Compliance Officer effective June 30, 2026, as he transitions to a regional role within P&G. He will be re-designated as a Non-Executive Director of the company starting July 1, 2026. Mr. Hegde's new role will be Vice President & Associate General Counsel – Market Operations, India, Middle East, Turkey & Africa.
Furthermore, Mr. Gaurav Bhartia will step down as Chief Financial Officer on June 30, 2026, to take up a new assignment within P&G. Concurrently, Ms. Srividya Srinivasan has been appointed as the new Executive Director and Chief Financial Officer, effective July 1, 2026. Ms. Srinivasan, who holds an MBA in Finance from the University of Virginia, Darden School of Business, brings over 20 years of experience in finance and has been with P&G since 2005, serving in various roles across different markets. Her appointment is for a period of five years, subject to shareholder approval at the upcoming 62nd Annual General Meeting. The company confirmed that Ms. Srinivasan is not debarred from holding such office and is not related to any existing directors.
What to do with a filing like this
Procter & Gamble Hygiene and Health Care Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Hygiene and Health Care Limited. Read the original for the full detail.